Drug Profile
GX 110
Alternative Names: GX-110; GX-110E; HB 110E; HB-110Latest Information Update: 11 Feb 2016
Price :
$50
*
At a glance
- Originator Dong-A Pharmaceutical; Genexine
- Developer Dong-A ST; Genexine
- Class DNA vaccines; Hepatitis B vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Hepatitis B
Highest Development Phases
- No development reported Hepatitis B
Most Recent Events
- 11 Feb 2016 No recent reports on development identified - Phase-II for Hepatitis B in South Korea (IM)
- 31 Jul 2013 Genexine completes a phase II trial in Hepatitis B in South Korea (NCT01813487)
- 30 Apr 2013 Genexine completes a phase I trial in Hepatitis B in South Korea (NCT01641536)